Entries |
Document | Title | Date |
20080207558 | Process for the Preparation of Trivalent Iron Complexes with Mono-, Di- and Polysaccharide Sugars - Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60° C. and 100° C. for a period between 1 and 4 hours at a pH between 9.0 and 11.0. | 08-28-2008 |
20080207559 | Carbohydrates mixture - A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed, | 08-28-2008 |
20080214493 | Use of Flavone Compounds as Potassium Channel Inhibitors - This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) using the leading flavone compound acacetin, and its derivatives and analogues that inhibit the ultra-rapidly-activating delayed rectifier potassium current (I | 09-04-2008 |
20080269163 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis - Described herein are methods for protecting cells from ultrasound-mediated cytolysis. | 10-30-2008 |
20080274998 | Disaccharide Molecules and Derivatives Thereof and Methods of Using Same - The present invention is of a method and compounds for mediating a biological activity mediated by moesin, and in particular, for such a method and compounds for mediating a biological activity that is capable of being mediated through binding of a disaccharide to moesin. | 11-06-2008 |
20090005339 | Methods of Treating Ear Infections - Methods of treating and/or preventing otitis media in a subject are provided. Methods of treating and/or preventing otitis externa are also provided. | 01-01-2009 |
20090048206 | Edible powder meterial having excellent shelf stability - The present invention provides a powder material obtained by drying an aqueous emulsion containing at least one component selected from the group consisting of perfumes, coloring agents and functional substances, trehalose and water-soluble hemicellulose. This powder material has excellent shelf stability of the perfume, coloring agent and/or functional substance, and can impart a desired fragrance, flavor, color and/or function stably to various drinks, foods, cosmetics and the like for a long period of time. | 02-19-2009 |
20090048207 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF - The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR. | 02-19-2009 |
20090069269 | ORAL COMPOSITION CONTAINING DIFRUCTOSE ANHYDRIDE - An oral composition for increasing equol production by inner-intestinal bacteria, wherein such composition contains difructose anhydride as an active ingredient to activate the equol production function of inner-intestinal bacteria. | 03-12-2009 |
20090099127 | Nematicidal Compositions and Methods - A nematicidal composition includes (a) at least one carbamate and (b) at least one neonicotinoid and/or chloronicotinyle. In one exemplary embodiment, the carbamate can be an oxime carbamate, such as thiodicarb and the neonicotinoid can be a nitroguanidine. In one specific embodiment, the nitroguanidine includes imidacloprid and/or clothianidin. An exemplary method of the invention includes applying a composition of the invention to either soil or a plant (e.g., seeds or foliarly) to combat nematode damage and/or increase crop yield. | 04-16-2009 |
20090118225 | 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury - The present invention is directed to nicotinamide derivatives, and their use in treating gastrointestinal disorders. | 05-07-2009 |
20090118226 | INTESTINAL EOSINOPHIL-SUPPRESSING COMPOSITION - To promote the growth of human beings or animals, prevent the onset of diarrhea and prevent or ameliorate various diseases, it is intended to provide a substance which has an effect of decreasing eosinophils in the intestinal tract and a feed comprising the same as a feed additive. Namely, an intestinal eosinophil-suppressing composition which contains an ▪-linked galactooligosaccharide as the active ingredient. When added in an amount of from 0.01 to 10% by weight, in terms of the saccharide, to an animal feed, this composition is useful in providing an intestinal eosinophil-suppressing feed. | 05-07-2009 |
20090137524 | SUBSTITUTED ARYLPYRAZOLES - This invention relates to a combination product comprising a compound of formula I | 05-28-2009 |
20090197828 | SYSTEM, METHOD AND PACKAGE FOR PROVIDING A SUCROSE SOLUTION - A solution of sucrose and water is packaged and placed in an aseptic state in a cup-shaped container with a removable cover for single patient use. A plurality of containers is shipped from a preparation site to a site of usage such as a hospital. A single container of the solution is opened at a site of a procedure for a neonatal infant, and the solution administered prior to the procedure as well as during or afterward, as needed for analgesic effect. Any residual solution is discarded after the procedure to prevent cross contamination of other patients. | 08-06-2009 |
20090209484 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR CALCIPENIA - The invention is to develop an agent having at least one of anricalclpenic, antiedemic and diuretic activities for humans or animals and to inhibit the postpartum drop of the calcium concentration in blood, thereby maintaining the health of the mother body and smoothing nursing and lactation. | 08-20-2009 |
20090215717 | Sulfated oligosaccharides - The invention relates to sulfated oligosaccharides, more particularly to new pharmaceutical uses of sulfated oligosaccharides. The invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic’, inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies. The invention further provides use of a sulfated oligosaccharide in the preparation of a medicament for the treatment of acute and chronic inflammatory disorders of the airways of mammals. The invention yet further provides use of a sulfated oligosaccharide to preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies. | 08-27-2009 |
20090215718 | CARBOHYDRATE COMPOSITION FOR FLAT GLUCOSE RESPONSE - A low-glycemic available carbohydrate composition of the invention contains the following components:
| 08-27-2009 |
20090221525 | FUNCTIONAL FOODS AGAINST TUMORS - The present invention relates to the technical field of functional foods, more precisely novel functional foods for the treatment and/or prevention of malignant carcinomas of the human or animal body, and also to processes for producing such functional foods. | 09-03-2009 |
20090247484 | Compounds - The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes, Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter. | 10-01-2009 |
20090270342 | IMMUNOREGULATORY AGENT - An object of the present invention is to provide an immunoregulatory agent, which can be continuously ingested on daily diet and has no fear of causing side effects, and a method for regulating immunity. The present invention solves the above object by providing an immunoregulatory agent comprising lactosucrose as an effective ingredient and a method for regulating immunity using lactosucrose. | 10-29-2009 |
20090281055 | PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY - The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound. The present invention also relates to a diluent for parenteral compounds. The diluent comprises palatinose or a derivative thereof. Another aspect of the present invention is directed to a method of decreasing the recovery time to pre-performance levels of total adenosine triphosphate (ATP) levels in a mammal comprising administering palatinose, or a derivative thereof, to the mammal. The present invention is further directed to a method of supplying a compound to a diabetic patient, burn victim patient or trauma victim patient. The method comprises administering palatinose, or a derivative thereof, in combination with the compound. | 11-12-2009 |
20090306011 | Use Of An Alkyl Glycoside Or Of A Mixture Of At Least Two Alkyl Glycosides As Agent Intended For Inhibiting Microbial Growth, And Compositions Containing It - The present invention relates to the use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, in particular in a cosmetic, pharmaceutical or food composition. | 12-10-2009 |
20090312281 | PROCESS FOR THE PREPARATION OF A PULVERULENT COMPOSITION AND PRODUCT AS OBTAINED - Method of preparing a non-hygroscopic pulverulent composition, includes a step for the spray drying, without an atomization support, of an aqueous solution containing at least one initially hygroscopic product, having a glass transition temperature ranging from 10° C. to 110° C., and a cryogenic fluid, especially a food-grade cryogenic fluid, or a mixture of cryogenic fluids, particularly chosen from liquid air, nitrogen and carbon dioxide, the aqueous solution being obtained by dissolving the cryogenic fluid in an initial aqueous solution containing the initially hygroscopic product. | 12-17-2009 |
20090318381 | Halogenated alkyl di-and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment - The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits. | 12-24-2009 |
20100004194 | USE OF ISOMALTULOSE IN FOOD PRODUCTS HAVING A REGENERATIVE EFFECT - The invention relates to the use of isomaltulose or mixtures of isomaltulose for the production of functional food products for improving the regeneration of individuals exposed to physical exertion. | 01-07-2010 |
20100022469 | ANTHELMINTHIC FORMULATIONS - The present invention relates to veterinary or pharmaceutical antiparasitic formulations which may comprise a macrocyclic lactone, one or more alcohol cosolvents and an oil wherein the crystallization of the macrocyclic lactone is minimalized. This invention also provides for, inter alia, antiparasitic formulations for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals, such as livestock. | 01-28-2010 |
20100029581 | NUTRITIONAL SUPPLEMENT - A nutritional supplement comprises about 2 parts roasted, ground flaxseed, about 2 parts of chick pea flour, about 1.5-2 parts of whole wheat or brown rice flour, about 1 part of raw, ground almonds and optionally, about 0.5-1 part of whole wheat bran. The supplement may additionally contain one or both of raw blue agave nectar and sunflower oil. The supplement may also contain cardamom and/or ginger. The nutritional supplement comprises at least about 1.5 grams of Omega-3 fatty acids, less than about 1.5 grams (g) of glucose, and less than about 0.6 g of sucrose in a serving of about 2 ounces (about 59 ml). A method of supplementing the nutrition of an individual comprises administering the nutritional supplement to the individual. | 02-04-2010 |
20100035837 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR VASOCONSTRICTION - An object of the present invention is to provide an agent for treating or preventing vasospasm. An object of the present invention is to provide an agent for treating or preventing cerebral vasospasm as well as arterial vasospasm. Further, an object of the present invention is to provide an agent for treating or preventing cerebral ischemia and cerebral infarction. | 02-11-2010 |
20100056469 | Pesticidal Active Mixtures Comprising Aminothiazoline Compounds - Pesticidal mixtures comprising aminothiazoline compounds The present invention relates to pesticidal mixtures comprising as active compounds 1) at least one aminothiazoline compound I of the Formula (I) wherein R | 03-04-2010 |
20100075918 | HYALURONIDASE INHIBITORS AS ANTI-CANCER AGENTS - Specific inhibitors of hyaluronidase (HYA1-type hyaluronidase) are used to treat cancer, especially carcinoma and solid tumors, and/or precancerous conditions. | 03-25-2010 |
20100093657 | LOW GLYCEMIC MIXTURES - The present invention relates to a food compound comprising an emulsion containing triglyceride oils as well as a low-glycemic saccharose isomer. | 04-15-2010 |
20100113382 | COMBINED USE OF DIPEPTIDYL PEPTIDASE 4 INHIBITOR AND SWEETENER - The present invention provides a novel therapeutic or preventive method, a pharmaceutical composition and use thereof, that exhibit superior anti-obesity effects (body weight-reducing (losing) effects and/or body fat mass-reducing effects). Specifically, the present invention provides a pharmaceutical composition comprising the combination of a dipeptidyl peptidase 4 inhibitor and a sweetener having a GLP-1 secretion-stimulating action, as well as use thereof for the manufacture of a medicament. The present invention also provides a method for treating or preventing obesity, comprising administering an effective amount of (a) a dipeptidyl peptidase 4 inhibitor and (b) a sweetener having a GLP-1 secretion-stimulating action to a patient suffering from symptoms of obesity. | 05-06-2010 |
20100130442 | Lung Injury Treatment - Techniques for lung injury treatment are provided. For example, a technique for treating a lung injury in a patient includes the step of administering a therapeutically effective amount of a sophorolipid to the patient. | 05-27-2010 |
20100152130 | TREATMENT OF CANCER WITH GLUTAMINE - Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine. | 06-17-2010 |
20100152131 | METHOD FOR PRODUCING PURIFIED HEMATINIC IRON-SACCHARADIC COMPLEX AND PRODUCT PRODUCED - A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals. | 06-17-2010 |
20100160251 | IMIDAZO COMPOUNDS - The present invention relates to the use of at least one lactose-derived C-glycoside of general formula (I): | 06-24-2010 |
20100168054 | Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation - The present invention relates to a novel process for the chemical synthesis of β-(1->6)-linked glucosamine disaccharides of the formula (1) and (intermediate) compounds relating to the process. According to further aspects the invention relates to compositions comprising the compounds and the use of the compounds in the synthesis of disaccharides and medicine. | 07-01-2010 |
20100168055 | COMBINATION OF MONOSACCHARIDE WITH C-GLYCOSIDE DERIVATIVE AND USE THEREOF - Composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, at least one of mannose, and rhamnose and at least one additional compound chosen from C-glycosides and C-glycoside derivatives. Use of such a composition, and also a device containing it. | 07-01-2010 |
20100190740 | OIL-IN-WATER EMULSION - The present invention relates to a composition in the form of an emulsion of the oil-in-water type formed of oily globules which are each provided with a lamellar liquid crystal coating and which are dispersed in an aqueous phase, wherein it has a pH ranging from 3 to 5.5 and in that it contains at least one lipophilic surface-active agent with an HLB ranging from 2 to 5, at least one hydrophilic surface-active agent with an HLB ranging from 8 to 12 and at least one amphiphilic compound of ionic nature at a pH ranging from 3 to 5.5. | 07-29-2010 |
20100204173 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. | 08-12-2010 |
20100204174 | NOVEL ACTIVE INGREDIENT IN CICATRIZATION AND USE THEREOF - The present invention relates to the use of a known compound as an agent for promoting and/or accelerating fibroblast proliferation and/or differentiation and, consequently, cicatrization. This compound is a copolymer of a 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid salt and of propenoic acid 2-hydroxyethyl ester. It may be used alone or in combination with other active substances for inducing or accelerating cicatrization. This compound, alone or in combination with another active substance, may be administered directly on the wound and the surrounding area or the mucous membranes, by topical application. It may also be used ex vivo, in particular for generating cells for skin grafts. | 08-12-2010 |
20100216738 | Acaricidal Active Substance Combinations - The present invention relates to the use of active substance combinations which consist firstly of a known dihydrofuranone derivative and secondly of further known pesticidal active substances, which active substance combinations are used for controlling animal pests, in particular from the order of the mites. | 08-26-2010 |
20100227835 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA - Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein. | 09-09-2010 |
20100234317 | USE OF DIFRUCTOSE ANHYDRIDE-CONTAINING COMPOSITION - A method for improving bowel movement of a subject desiring such an improvement, includes administering to the subject a defructose anhydride (DFA) in an amount effective to improve bowel movement. | 09-16-2010 |
20100249057 | TREHALOSE COMPOUND AND PHARMACEUTICAL COMPRISING THE COMPOUND - The object of the present invention is to provide a novel trehalose compound having a high affinity for an adenosine A3 receptor. The trehalose compound of the present invention is represented by General Formula (1): | 09-30-2010 |
20100249058 | FEED ADDITIVE AND FEED - To provide safe and easy means for preventing or treating diseases of birds and mammals, in particular, livestock. In particular, to provide means for preventing or treating an infectious disease caused by a Gram-positive bacterium. In addition, to improve fermentation in the rumen of a ruminant animal, to contribute to suppression of the generation of greenhouse gas, and to increase the feed efficiency. Mannosylerythritol lipids (MEL) and/or rhamnolipids are given to birds or mammals. | 09-30-2010 |
20100267658 | Trehalulose-containing composition, its preparation and use - The present invention relates to a trehalulose-containing composition, its preparation and use. | 10-21-2010 |
20100279978 | METHODS OF REDUCING THE SEVERITY OF MUCOSITIS - The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist. | 11-04-2010 |
20100298259 | PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME - The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one hyaluronic acid oligomer chosen from compounds containing from 1 to 6 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery. | 11-25-2010 |
20100323983 | PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF, AND USES THEREOF - The invention relates to the combination of hyaluronic acid and of at least one hyaluronic acid oligomer constituted of 1 to 2 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery. | 12-23-2010 |
20110009358 | AGENT FOR SUPPRESSING GLUCOSE LEVEL INCREASE, AGENT FOR SUPPRESSING BODY FAT ACCUMULATION AND FOOD COMPOUND - A method for reducing body fat accumulation is provided that includes: providing a reducer of body fat accumulation, wherein the reducer comprises isomaltulose; having an individual ingest the reducer; and having the individual consume a carbohydrate having an α-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides, wherein the reducer is ingested before or after or simultaneous with consuming the carbohydrate, and wherein the reducer reduces the individual's body fat accumulation caused by consuming the carbohydrate. The reducer of body fat accumulation includes isomaltulose (PALATINOSE™) as an active ingredient so that when the reducer is ingested and a carbohydrate having an α-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides is consumed, accumulation of body fat resulting from ingesting the carbohydrate is reduced. | 01-13-2011 |
20110021455 | STERILISED SUCRALFATE GEL - The present invention relates to an autoclave-sterilized gel comprising sucralfate and at least 15% by weight of a humectant, relative to the total weight of gel, and having a pH of greater than or equal to 6, more particularly for use in a skin healing treatment by topical application. | 01-27-2011 |
20110028424 | OIL-IN-WATER MICROEMULSION CARRYING LARGE AMOUNT OF OIL - An oil-in-water microemulsion is provided, which includes, on the basis of its total weight, the following components of A) 55-95 wt % of a water phase; B) 0.1-20 wt % of an oil phase, wherein the oil phase comprises at least one oil/fat component containing polyoxypropylene chains; and C) 1-25 wt % of an oil-in-water nonionic emulsifier, wherein the emulsifier is selected from the following group of: hydrophilic nonionic surfactants with polyoxyethylene chains as hydrophilic groups, polyglycerol fatty acid esters, polyglycerol fatty alcohol ethers, sucrose fatty acid esters, and hydrocarbyl polyglycosides. The oil-in-water microemulsion carries a large amount of oil. In addition, the use of an oil/fat containing polyoxypropylene chains is disclosed for increasing the amount of oil carried in an oil-in-water microemulsion. | 02-03-2011 |
20110028425 | Vesicle And Cosmetic Containing The Same - A vesicle according to the present invention is characterized in that it comprises a sucrose fatty acid diester and an acyl methyl taurate in an amount of 5 to 30 wt % relative to the diester and that the sucrose fatty acid diester is contained as a main component of membrane, and has excellent dispersion stability. Also the present invention includes a cosmetic comprising the vesicle and a lotion in which the vesicle is dispersed in a solvent containing alcohol. | 02-03-2011 |
20110071103 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects. | 03-24-2011 |
20110082102 | USE OF PREBIOTIC GALACTO-OLIGOSACCHARIDES IN THE TREATMENT OF INTESTINAL INFLAMMATION - The present invention relates to the use of an oligosaccharide, in particular a non-digestible oligosaccharide, composition in the prevention or treatment of inflammation, in particular intestinal inflammation. | 04-07-2011 |
20110098244 | Process for Isolating Sialic Acid Containing Oligosaccharides, and the Compositions Containing Sialic Acid Containing Oligosaccharides Obtainable Thereby - The invention relates to a process for isolating sialic acid containing oligosaccharides and in particular sialyllactose from a milk stream and especially from a whey stream. The process yields a product having a high content of sialyllactose and a low content of phosphorus compounds. This product is highly suitable to be included in infant foods. | 04-28-2011 |
20110105426 | COMPOSITIONS AND METHODS FOR TREATING CORNEAL INFLAMMATION - A method of treating corneal inflammation in a subject includes administering to the subject a therapeutically effective amount of a TLR4 antagonist. | 05-05-2011 |
20110124593 | Methods for determining chemotherapeutic agents targeting alpha-glucan pathways and uses thereof - The present invention provides methods for determining a putative antibacterial, the methods comprising determining whether the putative antibacterial inhibits GlgE or Rv3032. The present invention also provides the antibacterial, the pharmaceutical composition and the method of making the antibacterial as well as a method of treating a subject infected with a bacterial comprising administration of the antibacterial. | 05-26-2011 |
20110136757 | HYPERSULFATED DISACCHARIDE FORMULATIONS - Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof. | 06-09-2011 |
20110201569 | Methods For Treating Myocardial Disorders - Provided are methods for treating myocardial disorders comprising administering to a subject an effective amount of a compound of formula (I) | 08-18-2011 |
20110207694 | MAMMALIAN HYPOTHALAMIC NUTRIENT MODULATION OF GLUCOSE METABOLISM - Provided are methods of reducing glucose production in a mammal, methods of reducing food intake in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, methods of reducing peripheral blood glucose levels in a mammal, methods of decreasing serum triglyceride levels in a mammal, and methods of decreasing very low density lipoprotein (VLDL) levels in a mammal. | 08-25-2011 |
20110218171 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND - A trehalose compound having high immunopotentiating activity and low toxicity is represented by formula (1). (In the formula, X and X′ each represents a phenyl, a naphthyl, R | 09-08-2011 |
20110230437 | ORGANIC COMPOUNDS - A composition comprising a compound of formula I CH | 09-22-2011 |
20110237538 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES - Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase B; (h) Acid sphingomyelinase; (i) Galactocerebrosidase; (j) Acid ceramidase; (k) Arylsulfatase A; (l) alpha-L-Iduronidase; (m) Iduronate-2-sulfatase; (n) Heparan N-sulfatase; (o) alpha-N-Acetylglucosaminidase; (p) Acetyl-CoA: alpha-glucosaminide N-acetyltransferase; (q) N-Acetylglucosamine-6-sulfate sulfatase; (r) N-Acetylgalactosamine-6-sulfate sulfatase; (s) Acid beta-galactosidase; (t) Arylsulfatase B; (u) beta-Glucuronidase; (v) Acid alpha-mannosidase; (w) Acid beta-mannosidase; (x) Acid alpha-L-fucosidase; (y) Sialidase; and (z) alpha-N-acetylgalactosaminidase. | 09-29-2011 |
20110245196 | NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES - The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject. | 10-06-2011 |
20110245197 | HYPERSULFATED GLUCOPYRANOSIDES - Hypersulfated disaccharides, preferably octasulfated sucrose, with utility in asthma or asthma related disorders are disclosed. The compounds may optionally be formulated with pharmaceutically acceptable excipients or delivery agents. The delivery agents are selected from the group consisting of natural or synthetic polymers, aerosols or other vehicles that facilitate the delivery or administration of the drug. The hypersulfated disaccharides are made from carbohydrate starting materials. Ion exchange or other suitable synthetic processes may be utilized to prepare the pharmaceuticals. The hypersulfated disaccharides are useful as anti-inflammatory agents. | 10-06-2011 |
20110251153 | PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR HEMOGLOBINURIA OR MYOGLOBINURIA - A prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which may occur in humans or animals upon loading of exercise or stress or the like is provided. | 10-13-2011 |
20110275592 | EMULSION COMPOSITION AND FOOD AND COSMETIC PRODUCTS CONTAINING THE EMULSION COMPOSITION - The invention provides an emulsion composition obtained by mixing an oil phase containing a carotenoid having a melting point of 100° C. or more as detected when it is contained in an oil; and an aqueous phase containing a polyglycerol fatty acid ester and a nonionic emulsifier different from the polyglycerol fatty acid ester, wherein a weight ratio (A)/(B) of an amount (A) of the polyglycerol fatty acid ester to an amount (B) of the nonionic emulsifier different from the polyglycerol fatty acid ester is in the range of 2.5 to 10, and a particle diameter of dispersed particles that contain the carotenoid is 200 nm or less. | 11-10-2011 |
20110281816 | FUNGICIDALLY ACTIVE COMPOUND COMBINATIONS - The invention relates to novel fungicidally active compound combinations of 2′-cyano-3,4-dichloroisothiazole-5-carboxanilide of the formula | 11-17-2011 |
20110301116 | NSAIDS-INDUCED GASTROINTESTINAL MUCOSAL DISORDER ALLEVIATOR AND MANUFACTURING METHOD THEREOF - [Problems] The object of the present invention is to provide a Medical Drugs which reduce damage of gastrointestinal mucosal induced by NSAIDs. | 12-08-2011 |
20110306574 | INHIBITORS OF F18+ E COLI BINDING - The present invention relates to blood group A/B/H determinant on Type 1 Core glycosphingolipids chains as recognition point for the FedF protein of F18-fimbriated Enterotoxigenic and verotoxinogenic | 12-15-2011 |
20110312910 | PHARMACEUTICAL COMPOSITION BASED ON A HEPATOPROTECTOR AND A PREBIOTIC, AND PRODUCTION AND APPLICATION THEREOF - The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses. The invention contributes to the liver's functional recovery in a short time and prevents disease recidivation owing to the recovery of cholesterol exchange and intestinal biocenosis as a result of the synergistic interaction of a hepatoprotector and a prebiotic, thereby also preventing hepatoprotector side effects. | 12-22-2011 |
20120004192 | USE OF LACTULOSE IN THE TREATMENT OF AUTISM - A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity. | 01-05-2012 |
20120004193 | PROCESS FOR PRODUCTION OF ORALLY INGESTIBLE COMPOSITION CONTAINING ARABINOFURANOSYL VITEXIN, AND USE OF THE COMPOSITION - A method for producing an orally ingestible composition containing an arabinofuranosyl vitexin and/or a hydrolysate thereof by using | 01-05-2012 |
20120015901 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS - The present invention relates to a method of treating a life threatening condition in a critically ill human patient with a non-infectuous disorder, wherein the critically ill patient is a patient receiving enteral or parenteral nutrition, the method comprising the step of administering to said patient an autophagy inducing agent. | 01-19-2012 |
20120022016 | Compounds and methods for selectively targeting tumor-associated mucins - The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor. | 01-26-2012 |
20120071436 | METHOD, COMPOSITION AND KIT FOR ANTIGENIC BINDING OF NORWALK-LIKE VIRUSES - A method for preventing or treating an active Norwalk-Like Virus (NLV) infection in the gastrointestinal (GI) tract of a host, comprising the step of administering orally a fucosyl α1→2 carbohydrate compound to the host, the compound having a binding specificity of the antigenic determinant of a human histo-blood group antigen and competitively binds with a NLV at the determinant binding site of the NLV. The compound inhibits binding of the NLV in vivo to a histo-blood group antigen of the host, thereby inhibiting the active infection or preventing infection of the GI tract of the host by the NLV. | 03-22-2012 |
20120129802 | PROCESS FOR THE PRODUCTION OF ULTRAPURE GALACTO-OLIGOSACCHARIDES - The present invention describes a process for preparing ultrapure (≧95%) galacto-oligosaccharides (GOS), starting from GOS at lower purities by using sequential microbiological purifications involving | 05-24-2012 |
20120135955 | External Preparation Containing NSAIDs And Method For Producing The External Preparation - Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor. | 05-31-2012 |
20120157406 | METHOD OF PREVENTING DIARRHOEA - The present invention provides a method for the prevention of the incidence of and/or a reduction in the duration of acute diarrhoea, particularly in travellers, said method comprising orally administering an oligosaccharide composition, in particular a non-digestible oligosaccharide, to a mammal. | 06-21-2012 |
20120190641 | Use of Non-Digestible Oligosaccharides - Use of a non-digestible oligosaccharide or salt thereof for producing an anti proliferative effect in a subject wherein the non-digestible oligosaccharide is of formulae (i) [A]-[B] | 07-26-2012 |
20120190642 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. | 07-26-2012 |
20120190643 | CARBOHYDRATE COMPOSITION FOR FLAT GLUCOSE RESPONSE - A low-glycemic available carbohydrate composition of the invention contains the following components:
| 07-26-2012 |
20120202767 | HYALURONIC ACID BASED MUCOADHESIVE THERAPEUTIC COMPOSITION FOR THE PREVENTION AND TREATMENT OF EPITHELIAL AND MUCOSAL LESIONS OF THE HUMAN BODY - A sucralfate and hyaluronic acid based mucoadhesive composition of very low viscosity and its physiologically acceptable salts for the treatment and prevention of epithelial and mucosal lesions of the human body. | 08-09-2012 |
20120208782 | Modulation of Growth of Bifidobacteria Using a Combination of Oligosaccharides Found in Human Milk - A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of | 08-16-2012 |
20120245119 | METHOD FOR SEPARATING SIALYLLACTOSE MATERIAL - A method for easily and efficiently separating a sialyllactose material from a milk material is disclosed. The method comprises removing proteins from the milk material to obtain a protein-free liquid, adjusting the pH of the protein-free liquid to obtain a pH-adjusted liquid, and concentrating the pH-adjusted liquid by an ultrafiltration (UF) membrane. Since the method also allows separation of sialyllactose from lactose and minerals, sialyllactose can be obtained with high purity, making the sialyllactose material highly useful for food, pharmaceutical, and other applications. | 09-27-2012 |
20120245120 | ZINC SUCROSE OCTASULFATES, THEIR PREPARATION, AND PHARMACEUTICAL AND COSMETIC USES THEREOF - The present invention relates to a zinc sucrose octasulfate of the general formula I, a process for preparing same and its use in the pharmaceutical and/or cosmetic field | 09-27-2012 |
20120252754 | Candy Cakes - Hyperkalemic Periodic Paralysis is a disease in mainly stock type horses that can be treated by giving the horse light corn syrup. Currently, the easiest way to do this is with a syringe, which is actually very difficult. The invention is a treat that will deliver a specific amount of light corn syrup per treat. This makes the entire process of delivering the corn syrup easier, faster, cleaner, and actually enjoyable for the horse. The treat can be used as an abortive measure, and also as a preventative measure if the owner incorporates the treat into the horses' daily routine. In addition to being used as the treatment for the disease, it can also be used as a regular treat for HYPP positive horses. | 10-04-2012 |
20120270832 | KETONE ACCUMULATION INHIBITOR - A ketone body accumulation inhibitor that inhibits the accumulation of ketone bodies caused by exercising is provided in the present invention. The ketone body accumulation inhibitor contains isomaltulose as an active ingredient. | 10-25-2012 |
20120277181 | LACTULOSE FOR BOWEL EVACUATION - A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to a diagnostic, therapeutic or surgical procedure is disclosed. | 11-01-2012 |
20120295865 | SHARK-LIKE CHONDROITIN SULPHATE AND PROCESS FOR THE PREPARATION THEREOF - The present invention provides a shark-like chondroitin sulphate and a process for the preparation thereof. In particular, the present invention relates to a shark-like chondroitin sulphate, having a very low amount of 4-sulphate, a high charge density and a biological activity comparable to natural chondroitin sulphates. The invention also relates to a process for the preparation of said shark-like chondroitin sulphate affording substantially higher productivities and better reproducibility of product quality. The shark-like chondroitin sulphate of the invention shows a high molecular mass and its in vitro biological and anti-inflammatory effectiveness has been shown to be comparable to that of natural products making this polysaccharide potentially useful as a drug in pharmaceutical preparations and nutraceuticals. | 11-22-2012 |
20120295866 | Synthesis And Use Of Glycoside Pro-Drug Analogs - The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs. This invention relates to a method for the production of a broad group of glycosylated drugs, including but not limited to propofol, acetaminophen, and camptothecin carbohydrate derivatives. | 11-22-2012 |
20120309707 | SULPHATED DISACCHARIDES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR NEUROVASCULAR DISEASES - The present invention relates to the use of a series of sulphated disaccharides for the preparation of a medicament for the treatment or prevention of a neurodegenerative and/or neurovascular disease, of a traumatic brain injury or of a traumatic spinal cord injury. The present invention also relates to the use of said sulphated disaccharides for the preparation of a neuroprotective medicament or of an antioxidant medicament. The neurodegenerative and/or neurovascular diseases are preferably: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and stroke. | 12-06-2012 |
20120309708 | METHOD FOR TREATMENT OF LACTO-N-BIOSE-CONTAINING SOLUTION - The present invention relates to a method of treating a liquid composition containing lacto-N-biose, the method including: preparing a liquid composition containing lacto-N-biose having a pH at 25° C. of not less than 2.0 and not more than 5.5, and heating the liquid composition at a temperature of 65° C. or higher. The present invention can provide a treatment method that enables thermal decomposition of lacto-N-biose to be suppressed when a liquid composition containing lacto-N-biose is heated at a temperature of 65° C. or higher, a liquid preparation containing lacto-N-biose that is treated using the treatment method, a dried product produced from such a liquid preparation containing lacto-N-biose, and a method of producing a product containing lacto-N-biose. | 12-06-2012 |
20120329750 | METHOD FOR PRODUCING PURIFIED HEMATINIC IRON-SACCHARIDIC COMPLEX AND PRODUCT PRODUCED - A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals. | 12-27-2012 |
20130005680 | PHARMACEUTICAL COMPOSITION COMPRISING VITAMIN D ANALOGUE AND COSOLVENT-SURFACTANT MIXTURE - A topical pharmaceutical composition which is an oil-in-water-oil emulsion comprising a vitamin D derivative or analogue dissolved in a mixture of a non-ionic surfactant and a lower alkanol. The topical pharmaceutical composition may be used in the treatment of dermal conditions, such as psoriasis. | 01-03-2013 |
20130018014 | New class of therapeutics that enhance small molecule diffusion - The subject application relates to novel compositions containing a diffusion enhancing compound and their use in treating a variety of disorders. | 01-17-2013 |
20130079298 | NEW LOW MOLECULAR WEIGHT COMPLEXES BETWEEN IRON AND MALTOBIONIC ACID, USE THEREOF FOR INTRAMUSCULAR OR SUBCUTANEOUS ADMINISTRATION IN THE TREATMENT OF ANEMIC STATES, AND NEW PHARMACEUTICAL COMPOSITIONS ADAPTED FOR THESE USES - New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight. | 03-28-2013 |
20130085117 | Compositions Comprising Plant Material and Sugar For The Control of Pests and Methods of Making - Compositions and methods for controlling pests are described. The compositions comprise (a) a material obtainable from a plant comprising an effective amount of a glucosinolate breakdown product and (b) a sugar. The novel compositions exhibit improved properties over known formulations, for example with respect to their potency, ease of manufacture and ease of application. | 04-04-2013 |
20130123209 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects. | 05-16-2013 |
20130190266 | FRUCTOSYLATED PUERARIN, AND PREPARATION METHOD AND USE THEREOF - Fructosylated puerarin being converted from puerarin by a bioconversion method conducted in an aqueous phase or nonaqueous phase system, including monofructosyl-(2,6)-puerarin, bifructosyl-(2,6)-puerarin, trifructosyl-(2,6)-puerarin, tetrafructosyl-(2,6)-puerarin and pentafructosyl-(2,6)-puerarin. Tests have shown that the oligosaccharylated puerarin is effective to treat acute myocardial ischemia, and can markedly suppress in vitro the proliferation of human breast cancer cell strain MDA-MB-23 and human chronmyelogenors leukemia cell strain K562, and it has a low toxicity. | 07-25-2013 |
20130196942 | Composition for Skin Treatment - A composition comprising from 10 to 15% by weight of sucrose palmitate. The composition can be used to treat eczema. | 08-01-2013 |
20130203695 | HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS - Hypersulfated disaccharides of formula I and other hypersulfated disaccharides disclosed herein are used to treat diseases or conditions associated with human neutrophil elastase imbalances. The disaccharides and/or intermediates useful to prepare such compounds are prepared from heparin. The diseases and conditions which are treated with a compound of formula I include chronic obstructive pulmonary disorder (COPD) and cystic fibrosis (CF). The formulations are delivered to the lungs in an aerosol formulation or dry powder means or via nebulization. Oral forms are also suitable. | 08-08-2013 |
20130210759 | Composition for Use in the Treatment of Acne - A composition comprising from 10 to 15% by weight of sucrose palmitate which may be used in the treatment of acne. | 08-15-2013 |
20130225522 | COMPOSITION FOR RELIEVING STIMULUS OF SKIN CAUSED BY DYE - The present invention relates to a composition containing a carbohydrate or a derivative thereof as an active ingredient. The composition relieves stimulus of the skin caused by dye and prevents inflammation caused by dye. In addition, the present invention relates to a hair dye composition comprising a composition containing a carbohydrate or a derivative thereof as an active ingredient. The hair dye composition reduces stimulus of the skin and inflammation caused by dye. | 08-29-2013 |
20130225523 | GLYCODENDRIMERS OF POLYPROPYLETHERIMINE - A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting 16 terminal carboxylic acid groups, and b) conjugated to said core 2, 3, 4 or 5 glucosamine molecules, wherein each glucosamine is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions. | 08-29-2013 |
20130261076 | ADMINISTRATION OF ERITORAN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT ORTHOMYXOVIRUS INFECTIONS - The present invention is directed to methods for treating orthomyxovirus infections comprising administering to a subject an effective amount of a compound of formula (I) | 10-03-2013 |
20130261077 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS - The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: | 10-03-2013 |
20130316971 | USE OF TREHALOSE FOR PREVENTION OF NEURAL TUBE DEFECTS - Maternal diabetes suppresses autophagy in neuroepithelial cells of the developing neural tube which leads to neural tube defect formation. Trehalose treatment reversed autophagy impairment and prevented neural tube defects in diabetic pregnancies. Trehalose resolved homeostatic imbalance by correcting mitochondrial defects, dysfunctional proteins, ER stress, apoptosis, and delayed neurogenesis in the neural tubes exposed to hyperglycemia. Methods of using trehalose as an intervention against hyperglycemia-induced neural tube defects are provided herein. | 11-28-2013 |
20130331353 | CELL-PERMEABLE VARIANTS OF TREHALOSE AND METHODS FOR THE PROTECTION OF LIVING CELLS - A method for synthesizing variants of Tre; novel Tre variants; and a method for introducing Tre in sufficient concentration into the intracellular environment suitable to store treated mammalian cells, treat an aggregation disease, and protect treated cells from oxygen radicals are disclosed. | 12-12-2013 |
20130338097 | HISTONE INHIBITION - The invention relates to a method of inhibiting the cytotoxic activity of extracellular histones in a subject, comprising administering an effective amount of a polyanion to the subject. In particular the invention relates to a method for the treatment of patients who are suffering from sepsis and employs polyanions to rapidly form complexes with and thus neutralize or inhibit the cytotoxic activity of extracellular histone proteins, for example, those found in the blood circulation of sepsis patients. | 12-19-2013 |
20130345166 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects. | 12-26-2013 |
20130345167 | HYPERSULFATED DISACCHARIDE FORMULATIONS - Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof. | 12-26-2013 |
20140005139 | Cellooligosaccharide-containing composition | 01-02-2014 |
20140088036 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES - The present invention provides, among other things, phosphorylated and pyrophosphate derivatives of mono-, di- and oligosaccharides, as well as structural derivatives of these compounds. These compounds have a variety of uses including for pharmaceutical applications. Also provided are methods of use in the treatment of disease, including diseases related to oxygen delivery. | 03-27-2014 |
20140100189 | CARBOHYDRATES MIXTURE - A carbohydrate mixture for dietetic foods and pharmaceuticals is provided. The carbohydrate mixture comprises two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed. Carbohydrate component A may comprise at least one monosaccharide or of at least one oligosaccharide (disaccharide to hexasaccharide) or a mixture of two or more of these saccharides. Carbohydrate component B may comprise a polysaccharide (from heptasaccharide onwards) or a mixture of two or more polysaccharides. Carbohydrate component A=5 to 95 wt-% and carbohydrate component B=5 to 95 wt-% of the sum of the carbohydrate components A+B (=100 wt-%), and at least 80 wt-% of the carbohydrates/saccharides of both carbohydrate components have a prebiotic effect. The carbohydrate mixtures have not only a nutritive effect but they also stimulate health-promoting microorganisms present in the natural flora of the large intestine. | 04-10-2014 |
20140121179 | Novel Galactoside Inhibitor of Galectins - The present invention relates to a compound of the general formula (I): | 05-01-2014 |
20140121180 | SUCROSE OCTASULFATES OF MAGNESIUM, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COSMETIC USES OF SAME - The invention relates to a sucrose octasulfate of magnesium, having general formula I, the preparation method thereof and the use of same in the pharmaceutical and/or cosmetic field, wherein 0≦n≦4, n is an integer and Y represents OH, Cl, Br, I, NO | 05-01-2014 |
20140135281 | METHODS FOR CONTROLLING VARROA MITES - The present invention relates to methods and compositions comprising cyromazine for the control of bee mites and for the reduction of bee mite infestations, such as the control and reduction of infestations of parasitic bee mites, such as Varroa destructor in bee, preferably honey bee, colonies, and to the treatment of varroatosis in bees. | 05-15-2014 |
20140135282 | PHARMACEUTICAL COMPOSITION FOR USE IN INHIBITING RECURRENCE, AGGRAVATION AND METASTASIS OF HEPATOCARCINOMA - The present application provides a pharmaceutical composition for use in inhibiting recurrence, aggravation or metastasis of liver cancer, in which the pharmaceutical composition comprises at least one compound having a structure of formula (I) and a pharmaceutically acceptable vehicle. | 05-15-2014 |
20140142061 | OLIGOSACCHARIDES COMPOSITION FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME - The present invention relates to the use of a galactooligosaccharide composition for preventing or reducing the risk of developing metabolic syndrome. | 05-22-2014 |
20140155346 | COSMETIC AND/OR DERMATOLOGICAL USE OF OLIGOSACCHARIDE COMPOUNDS FOR PREVENTING AND TREATING STRETCH MARKS - The present invention relates to a topical composition, in particular a cosmetic and/or dermatological composition, to be used for preventing and/or treating stretch marks, including, in a physiologically acceptable medium, an effective amount of at least one synthetic polysulfated oligosaccharide having 1 to 4 glycose units, the salts thereof, and/or the derivatives thereof. The invention also relates to a cosmetic method, in particular for treating stretch marks, including at least one step of applying said composition to the skin. | 06-05-2014 |
20140162974 | METHODS FOR MODULATION OF PHOSPHORUS AND FGF23 - Compositions and methods for decreasing phosphorus, decreasing cFGF23, or increasing iFGF23 in a subject. Such compositions and methods can be useful for treatment of conditions, disorders, or diseases associated with phosphorus or FGF23 disregulation. | 06-12-2014 |
20140187512 | USE OF LACTULOSE IN THE TREATMENT OF AUTISM - A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity. | 07-03-2014 |
20140187513 | METHOD OF IMPROVING SKILLS WITH A COMPOSITION COMPRISING NON-DIGESTIBLE SACCHARIDE - The present invention concerns a therapy aimed at language and/or social skills in infants through administration of components stimulating the development of a healthy intestinal flora. | 07-03-2014 |
20140200194 | USE OF URARIA IN PROMOTING OSTEOGENESIS OR PROVIDING NEUROPROTECTION - The invention provides a method for promoting osteogenesis, increasing bone mass or enhancing the rate of bone growth, which comprises administering to a subject an effective amount of | 07-17-2014 |
20140235570 | THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS - The invention relates to a composition for the treatment of perianal disorders. In particular, the composition includes three components: a) an analgesic, b) a cryoprotective agent and c) a muscle relaxant. | 08-21-2014 |
20140243284 | BIOLOGICALLY ACTIVE MACROLIDES, COMPOSITIONS, AND USES THEREOF - The present invention provides a compound of the formula (I) or (II), wherein R | 08-28-2014 |
20140303114 | METHOD FOR THE EXTRACTION OF FURAN DERIVATIVE COMPOUNDS FROM SEEDS OF HASS AVOCADO (Persea americana Mill) AT LOW TEMPERATURE AND THEIR USE AS REPELLENTS AND MITICIDES AGAINST Tetranychus urticae, Tetranychus cinnabarinus, Oligonychus yothersi, Panonychus citri, and Brevipalpus chilensis. - This invention relates to the extraction and use of bioactive compounds from avocado seeds (var. Hass; | 10-09-2014 |
20140303115 | LACTULOSE FOR BOWEL EVACUATION - A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to a diagnostic, therapeutic or surgical procedure is disclosed. | 10-09-2014 |
20140323429 | NSAIDS-INDUCED GASTROINTESTINAL MUCOSAL DISORDER ALLEVIATOR AND MANUFACTURING METHOD THEREOF - A method of manufacturing a medical drug of alleviating damage of gastrointestinal mucosal induced by a non-steroidal anti-inflammatory drug, NSAID, the medical drug being able to induce anti-inflammatory effect of the NSAID and being able to alleviate damage induced by the NSAID includes dissolving trehalose and the NSAID into one or more solutions, so as to obtain an approximately homogenously-mixed liquid mixture of the trehalose and the NSAID; in which the liquid mixture contains an intermolecular compound with the trehalose and the NSAID; and drying the liquid mixture so as to obtain the medical drug. | 10-30-2014 |
20140336144 | External Preparation Containing NSAIDS And Method For Producing The External Preparation - Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor. | 11-13-2014 |
20140336145 | COMPOSITIONS AND METHODS FOR TREATING OCULOPHARYNGEAL MUSCULAR DYSTROPHY - The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of oculopharyngeal muscular dystrophy (OPMD). | 11-13-2014 |
20140336146 | Novel galectoside inhibitors of galectins - The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands in a mammal, wherein said galectin is preferably a galectin-3. The novel compounds are defined by the general formula (I). | 11-13-2014 |
20140343010 | CO-CRYSTALS OF DAPAGLIFLOZIN - The present invention provides novel co-crystal forms of dapagliflozin, namely a dapagliflozin lactose co-crystal and a dapagliflozin asparagine co-crystal, to pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating type 2 diabetes. | 11-20-2014 |
20150018302 | COMPOSITIONS COMPRISING NDGA DERIVATIVES AND SORAFENIB AND THEIR USE IN TREATMENT OF CANCER - The present invention provides pharmaceutical compositions comprising derivatives of NDGA, including M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib and their use in the inhibition and treatment of neoplastic diseases, such as liver cancer, colon cancer, breast cancer, brain cancers and ovarian cancers, for example, in a subject. Compositions comprising derivatives of NDGA, including M4N, sorafenib and additional therapeutic agents are also provided. | 01-15-2015 |
20150025034 | COMPOSITION FOR CARE AND HYGIENE OF THE AUDITORY CANAL - The aim of the invention is to propose a composition for the care and hygiene of the auditory canal, in particular a cerumenolytic composition, which is effective for dissolving and preventing the appearance of plugs of cerumen, which is free from products irritating to the auditory canal or a source of allergy, such as preservatives or surfactants of animal origin, which is biodegradable and non-toxic for the environment, which can be used under non-sterile conditions while ensuring satisfactory preservation and stability and which does not require rinsing after use thereof. To this end, the invention concerns a composition for the care and hygiene of the auditory canal that is characterised in that it comprises a pair of surfactants consisting of an N-acyl sarcosinate sodium salt having an HLB greater than or equal to 25 and a sucrose fatty acid ester having an HLB greater than or equal to 11. | 01-22-2015 |
20150025035 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME - The invented inositol and trehalose derivatives, prepared by introducing multiple units of the guanidine group to the backbone molecules, show excellent blood-brain barrier permeability, and accordingly, it can be easily transported to the brain tissues and utilized for the treatment of neurodegenerative diseases such as Alzheimer's disease and Huntington's disease. | 01-22-2015 |
20150038454 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE - Compositions comprising an antimicrobial effective concentration of sucralose and methods of using for treating pharyngeal and other bacterial conditions. | 02-05-2015 |
20150038455 | HEPARAN SULFATE/HEPARIN MIMETICS WITH ANTI-CHEMOKINE AND ANTI-INFLAMMATORY ACTIVITY - The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods. | 02-05-2015 |
20150038456 | Stable Hydrogel Compositions Including Additives - The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. | 02-05-2015 |
20150045320 | METHODS AND COMPOSITION FOR INDUCING SATIETY - A flowable or spoonable medicament, food, food ingredient or food supplement is useful for inducing satiety. It comprises (a) one or more mono-, di- and/or oligosaccharides and (b) a methylcellulose, wherein the methylcellulose has anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is from 0.17 to 0.36, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups. | 02-12-2015 |
20150065450 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION - The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (HA), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the CD44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug. | 03-05-2015 |
20150072952 | GLYCOMIMETICS TO INHIBIT PATHOGEN-HOST INTERACTIONS - The present invention relates to novel glycomimetic compounds that are rationally designed to inhibit the binding of various pathogens to cell surface sialylated galactose and methods of use thereof. Specifically sialic acid glycosides and C-glycosides are disclosed that form a lactam ring structure or a cyclic ether/amine ring structure with the adjacent monosaccharide residue. | 03-12-2015 |
20150080331 | GLUTAMINE & TREHALOSE COMPOSITIONS - Pharmaceutical compositions comprising glutamine and trehalose for treating side effects to oncology treatments are disclosed. | 03-19-2015 |
20150087615 | COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING METASTASIS - Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker. | 03-26-2015 |
20150094278 | METHODS OF DIAGNOSING, GRADING, MONITORING, AND TREATING HEPATIC ENCEPHALOPATHY - The present disclosure provides methods, systems, and instruments for the determination by a physician or medical professional whether a subject is experiencing or has recently experienced an overt HE episode and for grading overt HE episodes as well as methods, systems, instruments and tools for screening for overt HE episodes by a non-medical professional such as a caregiver. Also provided are methods of treating HE episodes and methods of monitoring HE episode treatment that incorporate these methods, systems, instruments, and tools. | 04-02-2015 |
20150126472 | STRAIN PRODUCING TURANOSE AND USES THEREOF - The present invention relates to a strain of | 05-07-2015 |
20150133398 | Prebiotic Formulations and Methods of Use - The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes. | 05-14-2015 |
20150141367 | MODULATION OF GROWTH OF BIFIDOBACTERIA USING A COMBINATION OF OLIGOSACCHARIDES FOUND IN HUMAN MILK - A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of Bifidobacteria in the gut. The formulation may be an infant formula. | 05-21-2015 |
20150306120 | INHIBITING INFLAMMATION WITH MILK OLIGOSACCHARIDES - A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides. | 10-29-2015 |
20150320780 | MIXTURE OF FUCOSYLATE LACTOSES - A method to form a mixture containing at least one of 2′-FL (2′-O-fucosyllactose, Fuc(α1-2)Gal(β1-4)Glc) and 3-FL (3-O-fucosyllactose, Gal(β1-4)[Fuc(α1-3)]Glc) characterized in that DFL (difucosyl-lactose, Fuc(α1-2)Gal(β1-4)[Fuc(α1-3)]Glc) is subjected to partial hydrolysis, e.g. enzymatic hydrolysis or acid hydrolysis. | 11-12-2015 |
20150328154 | METHOD FOR INCORPORATING ACTIVE AGENTS INTO A HYDROPHILIC POLYMER FOAM - The present invention consists of a novel process for the incorporation of one or more water-soluble active agents in a hydrophilic polymer foam. Said process makes it possible in particular to obtain a hydrophilic polyurethane foam exhibiting a gradient of active agents. This process is of particular use when manufacturing hydrophilic polyurethane foams intended for medical, cosmetic and dermocosmetic purposes. | 11-19-2015 |
20150359898 | Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed Complexes - A complex comprises pemetrexed and a coformer. A pharmaceutical composition comprises a complex of pemetrexed and a co-former and one or more pharmaceutically acceptable excipients. | 12-17-2015 |
20150374644 | Therapeutic Composition for the Treatment of Perianal Disorders - A composition for the treatment of perianal disorders. In particular, the composition includes three components: a) an analgesic, b) a cryoprotective agent and c) a muscle relaxant. | 12-31-2015 |
20150374661 | BIOLOGICALLY ACTIVE MACROLIDES, COMPOSITIONS, AND USES THEREOF - The present invention provides a compound of the formula (I) or (II), wherein R | 12-31-2015 |
20160002733 | ASSESSING RISK FOR ENCEPHALOPATHY INDUCED BY 5-FLUOROURACIL OR CAPECITABINE - Methods and systems are provided for determining susceptibility to 5-fluorouracil (5-FU) or capecitabine toxicity. Methods are provided for treating a human subject based on a determined susceptibility to 5-fluorouracil (5-FU) or capecitabine toxicity. | 01-07-2016 |
20160022716 | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTONS DISEASE - The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of Huntington's disease. | 01-28-2016 |
20160022717 | ADMINISTRATION OF ERITORAN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT ORTHOMYXOVIRUS INFECTIONS - The present invention is directed to methods for treating orthomyxovirus infections comprising administering to a subject an effective amount of a compound of formula (I) | 01-28-2016 |
20160030459 | COMPOSITIONS AND METHODS FOR TREATING ALLERGIC CONDITIONS - Compositions and methods are provided herein for treatment of allergic conditions, by administration of an adjuvant composition, with or without allergen. | 02-04-2016 |
20160030466 | USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR IMPROVING BONE DEVELOPMENT AND FORMATION AND/OR FOR IMPROVING COGNITIVE AND CNS DEVELOPMENT IN OFFSPRING - The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant and/or lactating woman for improving one or more characteristics in offspring, for example cognition and/or bone health. The carbohydrate system may include a slow rate of digestion simple carbohydrate, a complex carbohydrate, and a non-absorbent carbohydrate and/or an indigestible carbohydrate. | 02-04-2016 |
20160033473 | INDOXYL SULFATE AS A BIOMARKER OF PREBIOTIC EFFICACY FOR WEIGHT GAIN PREVENTION - The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to indoxyl sulfate as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain. | 02-04-2016 |
20160076013 | A MUTANT SIALIDASE HAVING TRANS-SIALIDASE ACTIVITY FOR USE IN PRODUCTION OF SIALYLATED GLYCANS - The invention provides a mutant enzyme having trans-sialidase activity (EC 3.2.1.18), characterized by an enhanced trans-sialidase:sialidase ratio when compared to its parent sialidase enzyme. Further the enzyme may be used in a method for trans-sialylating mono- and oligo-saccharides, including galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), malto-oligosaccharides (MOS), isomalto-oligosaccarides (IMO), lactulose, melibiose, maltose, glycosyl sucrose, lactosucrose and fucose. Trans-sialidated mono- and oligo-saccharides, produced with the mutant enzyme, are useful in preparing infant formula, a prebiotic nutritional supplement, and a food supplement. | 03-17-2016 |
20160096861 | Novel galactoside inhibitor of galectins - Provided is a compound of the general formula (I): | 04-07-2016 |
20160101122 | COMPOSITIONS AND METHODS FOR TREATING SPINOCEREBELLAR ATAXIA - The present invention provides alleviating a sign or symptom of spinocerebellar ataxia by administering an injection of an aqueous formulation comprising trehalose. | 04-14-2016 |
20160102115 | NOVEL METHOD FOR SYNTHESIZING N-ALKYL-GLYCOSYL(DI)AMINE DERIVATIVES AND USES OF SAME AGAINST PHYTOPATHOGENS - The present invention relates to a novel method for synthesising, without a solvent, N-alkyl-glycosyl(di)amine derivatives represented by the following general formula (I): The invention also concerns the use of N-alkyl-glycosyl(di)amine derivatives represented by the general formula (I), and N-alkyl-glycosyl(di)ammonium quaternary salts represented by the general formula (II) and N-alkyl-glycamine derivatives represented by the general formula (III) obtained from N-alkyl-glycosyl(di)amine derivatives represented by the general formula (I), as antibacterial and/or antifungal agents against phytopathogens. | 04-14-2016 |
20160103140 | Methods for Diagnosis and Treatment of Concussion or Brain Injury - This invention relates to compositions and methods for diagnosing and treating concussion/mTBI. | 04-14-2016 |
20160108447 | PROCESS FOR THE PRODUCTION OF ULTRAPURE GALACTO-OLIGOSACCHARIDES - The present invention describes a process for preparing ultrapure (≧95%) galacto-oligosaccharides (GOS), starting from GOS at lower purities by using sequential microbiological purifications involving | 04-21-2016 |
20160113960 | TOPICAL PREPARATIONS COMPRISING HYALURONIC ACID, VERBASCOSIDE AND GLYCEROPHOSPHOINOSITOL - The present invention relates to new synergistic associations of hyaluronic acid sodium salt (HANa), verbascoside (VB) and glycero-phospho-inositol (GPI), and the use of said associations in therapy, in particular in the topical treatment of inflammatory and painful conditions of the mucosa and/or skin, such as dermatitis, acne, psoriasis, ulcers, decubitus ulcers, phlebitis, hemorrhoids, and in particular vulvodynia and urethritis. | 04-28-2016 |
20160120798 | TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE - Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose. Also disclosed is an injectable aqueous pharmaceutical formulation comprising a therapeutically effective amount of trehalose. | 05-05-2016 |
20160129028 | PHARMACEUTICAL COMPOSITIONS - Described herein are pharmaceutical compositions comprising a LMWH preparation having at least one chain having a glycol split uronic acid residue (UG) in the preparation and uses thereof. | 05-12-2016 |
20160129029 | THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT WITH CAPSIANOSIDE-TYPE COMPOUNDS - The present invention discloses the use of certain compounds as therapeutic agents, and in particular as analgesics and anti-inflammatory agents. Such compounds include, for example, certain diterpene monoglycosides and diterpene diglycosides. The compounds of the present invention may be synthesized or isolated from the fruit of the genus | 05-12-2016 |
20160136193 | TREATMENT OF SYMPTOMS ASSOCIATED WITH BACTERIAL VAGINOSIS - The invention relates to the use of saccharide, such as lactose for the preparation of a medicament for the treatment and/or prophylaxis of one or more symptoms caused by bacterial vaginosis, wherein the medicament comprises at least 20 percent by weight of saccharide, and wherein the medicament is substantially free from bacteria. Furthermore, the invention relates to a method for treating one or more symptoms associated with bacterial vaginosis, as well as a pharmaceutical composition comprising the saccharide. | 05-19-2016 |
20160143930 | COMBINATION OF PENTACYCLIC TRITERPENES AND HYDROXYTYROSOL AND DERIVATIVES THEREOF - The present invention is related to a product comprising a pentacyclic triterpene and hydroxytyrosol or derivatives thereof, uses, and pharmaceutical composition thereof. | 05-26-2016 |
20160166489 | GEL-BASED SUGAR SCRUB | 06-16-2016 |
20160184335 | ANTITUMOR AGENT - The objective of the present invention is to provide a highly safe antitumor agent having excellent antitumor activity and few side effects. The antitumor agent of the present invention is characterized in that it contains cellobiose as an active ingredient. | 06-30-2016 |
20160250242 | HYPERSULFATED DISACCHARIDE FORMULATIONS | 09-01-2016 |